ClinicalTrials.gg
RecruitingNCT06596824PROTO-WP4Updated Mar 2, 2026

Personalized Digital Training Intervention to Reduce Inflammation by Correcting Pathological Movement Patterns in Pre-stage Knee Osteoarthritis After Anterior Cruciate Ligament Reconstruction

An interventional study of Training intervention in Osteoarthritis (OA) of the Knee and ACL Reconstruction, sponsored by Charite University, Berlin, Germany. Recruiting at 2 sites in Germany. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Osteoarthritis with a site in Germany — 12 open to participants now, 27 under way, 3 of them phase 3. Osteoarthritis · Germany.

Planned enrollment
68th of 98
60 · median 139
Started
2024
with 5 others
No phase
36 of 131
5 open now
Primary completion
2027-10
later than 14 of 26 live
Registered
123rd of 131
by date
Lead sponsor
4 of 131
Charite University, Berlin, Germany

Among the 131 studies in Osteoarthritis with a site in Germany, this one is the 68th largest by planned enrollment of the 98 interventional ones that give a count, is one of 6 that started in 2024, is one of 36 with no phase, reaches primary completion later than 14 of the 26 other live ones, and was the 123rd registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

12 of the 131 studies in Osteoarthritis with a site in Germany are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Osteoarthritis with a site in Germany, or all of them as a file.
02

Study summary

Osteoarthritis (OA) is a condition that causes pain and stiffness in the joints, often due to injuries like torn ligaments. Even after surgery, these injuries can lead to long-term joint problems. Current treatments don\'t fully prevent OA from developing. This study is testing a new 12-week exercise program designed to improve how the knee moves, using a special sensor-based system. The goal is to reduce joint inflammation and prevent the development of OA in patients who have had knee surgery.

03

Conditions studied

  • Osteoarthritis (OA) of the Knee
  • ACL Reconstruction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Adult subjects between 18 to 50 years old at the time of screening
  • Primary ACL reconstruction within a maximum of 6 months after a unilateral ACL injury
  • Complete baseline assessment between 8 and 12 weeks after ACL reconstruction

Exclusion criteria

Exclusion Criteria:

  • Significant trauma to a weight-bearing joint within 12 months prior to study initiation (excluding the ACL injury)
  • Previous surgeries on the study knee (except for the ACL reconstruction)
  • Signs of knee OA as defined by the OARSI-Joint Space Narrowing (JSN) Score of two or more (standing AP x-ray)
  • Physical activity level: Tegner activity score before injury of 0-2 (very low activity) or 8-10 (very high activity)
  • ≥ 30 kg/m2;
  • Inflammatory arthropathies;
  • due to illness or medication;
  • Sepsis or hemostasis disorders;
  • Severe uncontrolled inflammatory disease or disease (e.g., ulcerative colitis, Crohn's disease, etc.);
  • Having and undergoing treatment including chemotherapy, radiotherapy, or immunotherapy;
  • for MRI, including pacemakers, defibrillators, metal implants, pregnancy, sensorineural hearing loss above 30 dB, tinnitus and claustrophobia
  • Unable to freely give their (e.g., individuals under legal guardianship).
  • Currently enrolled in or has not yet completed a period of at least 5 times as the half-life time of the drug used in the previous trial since ending other device or drug trial(s)
  • Patients who are dependent on the sponsor, investigator, or study site;
  • Pregnant or breast-feeding women or women of not protected by an effective method of birth control (defined as pearl index \< 1);
  • Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel;
  • Patients who are committed to an institution by virtue of an order issued by either the judicial or the administrative authorities;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    The treatment group

    In addition to the standard-of-care physiotherapy program, the treatment group will additionally receive a training intervention utilizing sensor-based technology that provides 3D avatar training, supported by an accompanying app, to deliver personalized exercise regimens. This intervention aims to correct the pathological knee movement and loading patterns that exacerbate joint inflammation and contribute to the development of knee OA.

    Behavioral: Training intervention

  • No intervention
    the control group

    Standard-of-care physiotherapy program

Interventions

  • BehavioralTraining intervention

    Personalized digital training intervention aims to correct pathological knee movement and loading patterns and reduce inflammation in pre-stage knee osteoarthritis.

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    Restoration of normal knee angle and moment patterns during walking at 6-month follow-up (compared to normative data), as determined by a machine learning-derived gait index.

    Time frame: at 6-month follow-up visit

Secondary outcomes

  1. Secondary Endpoint: Cartilage Thickness

    Quantitative magnetic resonance imaging measurement of cartilage thickness, expressed in millimeters (mm), across predefined articular sub-regions of the knee.

    Time frame: Baseline, 6, and 36 months follow-up visits

  2. Secondary Endpoint: Cartilage Volume

    Quantitative magnetic resonance imaging measurement of cartilage volume, expressed in cubic millimeters (mm³), across predefined articular sub-regions of the knee.

    Time frame: Baseline, 6, and 36 months follow-up visits

  3. Secondary Endpoint: Cartilage Composition

    Quantitative magnetic resonance imaging measurement of cartilage composition using laminar T2 relaxation time, expressed in milliseconds (ms), reflecting cartilage water content and collagen organization across predefined articular sub-regions of the knee.

    Time frame: Baseline, 6, and 36 months follow-up visits

  4. Secondary Endpoint: Meniscus Position

    Quantitative magnetic resonance imaging measurement of meniscus extrusion, expressed in millimeters (mm), defined as the distance the meniscus extends beyond the edge of the tibial plateau.

    Time frame: Baseline, 6, and 36 months follow-up visits

  5. Secondary Endpoint: Hoffa Synovitis

    Quantitative magnetic resonance imaging measurement of Hoffa synovitis, expressed as a signal distribution pattern (dimensionless) within the infrapatellar (Hoffa's fat pad) region.

    Time frame: Baseline, 6, and 36 months follow-up visits

  6. Secondary Endpoint: Effusion Synovitis

    Quantitative magnetic resonance imaging measurement of joint effusion and synovitis, expressed as synovial fluid volume in cubic millimeters (mm³).

    Time frame: Baseline, 6, and 36 months follow-up visits

  7. Secondary Endpoint: Magnetic Resonance Imaging Osteoarthritis Knee Score (MOAKS)

    Semi-quantitative assessment of structural pathology using the Magnetic Resonance Imaging Osteoarthritis Knee Score (MOAKS), where scores range from 0 (no cartilage damage) to 3 (severe cartilage damage), with higher scores indicating greater pathology, across fourteen articular sub-regions.

    Time frame: Baseline, 6, and 36 months follow-up visits

Other outcomes

  1. Exploratory Endpoint: Biomarkers of Joint Tissue Remodeling

    Circulating and synovial fluid markers of joint tissue remodeling (e.g., CTX-I, CTX-II, PRO-C2, C1M) will be measured using validated immunoassays with detection limits in the nanogram-per-milliliter (ng/mL) range.

    Time frame: Baseline, 6, and 36 months follow-up visits

  2. Exploratory Endpoint: Inflammatory Cytokines

    Plasma or serum concentrations of inflammatory cytokines and soluble mediators (e.g., TNF-α, G-CSF, IFN-γ, IL-6) will be determined using validated multiplex immunoassays with detection limits in the picogramm-per-milliliter (pg/mL) range.

    Time frame: Baseline, 6, and 36 months follow-up visits

  3. Exploratory Endpoint: Cellular Biomarkers

    Immune cell subpopulations in peripheral blood and synovial fluid are analyzed by standardized multiparameter flow cytometry for basic phenotyping of T cells, B cells and myeloid cell populations and reported either as absolute or relative cell count.

    Time frame: Baseline, 6, and 36 months follow-up visits

07

Study locations

2 of 2 sites recruiting
  • Charité - Universitätsmedizin Berlin, BeMoveD - Berlin Movement Diagnostics
    Berlin, 10117, Germany
    Recruiting
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Oct 2027, 37 months after the start.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 37 months is above that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Oct 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06596824
Responsible party
Tobias Winkler (Prof. Dr.med., Charite University, Berlin, Germany) — Principal investigator
First posted
Sep 19, 2024
Start date
Sep 1, 2024
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Winkler, Prof. Dr.med.
Contact
tobias.winkler@charite.de
+49 30 450 559084

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion